Request an invite
Atlas/Cell therapy/MACI/Skipped studies

MACI: genotox, carcinogenicity and repro: done or skipped?

autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
Check my plan vs. these
Genotoxicity
Not conducted on cells; four studies on collagen membrane were non-mutagenic
“Four studies ( in vitro and in vivo ) were conducted to assess the genotoxic potential of the collagen membrane.”
✓ VerifiedUS prescribing informationSource ↗
Carcinogenicity
Not conducted (avascular local site, differentiated cells, no systemic distribution)
“Studies to evaluate the carcinogenicity or impairment of fertility potential of MACI have not been performed.”
✓ VerifiedUS prescribing informationSource ↗
Reproductive & developmental
Not conducted (local administration, minimal systemic entry, mature autologous cells)
“Per the applicant, studies were not conducted to evaluate this safety endpoint because the product is administered locally in the knee with minimal to no product entry systemically.”
✓ VerifiedFDA pharmacology/toxicology review, p. 24Source ↗
Safety pharmacology
Not conducted
“No safety pharmacology studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 23Source ↗

Same question, other cell therapies

Abecma

idecabtagene vicleucel · BCMA CAR-T
Not conducted (traditional); insertion site analysis of 20 clinical lots

Alofisel

darvadstrocel · Allogeneic adipose MSC
Not conducted; cell-based product does not interact with DNA

Amtagvi

lifileucel · TIL therapy
Not conducted (not warranted given product characteristics and biological activity)

Aucatzyl

obecabtagene autoleucel · CD19 CAR-T
Not conducted (third-generation SIN lentiviral vector, release criterion, long-term clinical monitoring for insertional mutagenesis)

Breyanzi

lisocabtagene maraleucel · CD19 CAR-T
Not conducted (traditional); lentiviral integration site mapping instead

Carvykti

ciltacabtagene autoleucel · BCMA CAR-T
Not conducted (classical); lentiviral integration site analysis instead

ChondroCelect

characterised viable autologous cartilage cells · Autologous chondrocytes
Not conducted (per cell-based product guideline)

Ebvallo

tabelecleucel · EBV-specific allogeneic T cells
Not conducted (ICH S6(R1)); non-genetically engineered cells

Encelto

revakinagene taroretcel · CNTF (encapsulated RPE cell implant)
Done: ISO-10993 battery (bacterial, mammalian cell, mouse micronucleus on device extracts), negative

Gintuit

allogeneic cultured keratinocytes and fibroblasts in bovine collagen · Allogeneic keratinocytes + fibroblasts
Not conducted (nature of product and clinical experience)

Holoclar

autologous corneal epithelial cells containing limbal stem cells · Autologous limbal stem cells
Not conducted (classical); in vitro karyotype analysis of cells

Kymriah

tisagenlecleucel · CD19 CAR-T
Not conducted (classical); lentiviral integration site analysis on 14 donor products

Lantidra

donislecel · Allogeneic pancreatic islets
Not conducted

Laviv

azficel-T · Autologous fibroblasts
Not conducted (autologous nature, prior human experience)

Omisirge

omidubicel · Expanded cord blood HPC
No standard genotox; cytogenetic/karyotype analyses of CF and NF showed no clonal aneuploidy

Provenge

sipuleucel-T · PAP-GM-CSF (autologous APC)
Not conducted (autologous nature of product)

Rethymic

allogeneic processed thymus tissue · Allogeneic thymus tissue
Not conducted

Ryoncil

remestemcel-L · Allogeneic BM-MSC
Not conducted (not warranted)

Spherox

spheroids of autologous matrix-associated chondrocytes · Autologous chondrocyte spheroids
Not conducted (per cell-based product guideline)

StrataGraft

allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen · Allogeneic keratinocytes + fibroblasts
Not conducted

Tecartus

brexucabtagene autoleucel · CD19 CAR-T
Not conducted (traditional); vector integration site analysis performed instead

Tecelra

afamitresgene autoleucel · MAGE-A4 TCR-T
Not conducted (no test models or relevant species); integration site analysis showed polyclonal products, no selective insertion

Tregzi

allogeneic Treg immunotherapy with HSPC and T cells (Orca-T) · Allogeneic Treg + HSPC + Tcon
Not conducted

Yescarta

axicabtagene ciloleucel · CD19 CAR-T
Not conducted; literature review of retroviral-transduced T-cell transformation risk instead

Zalmoxis

allogeneic T cells modified with HSV-TK / dLNGFR (nalotimagene carmaleucel) · HSV-TK suicide-gene T cells
Not conducted; in vitro retroviral integration site analysis instead

Zemcelpro

dorocubicel · UM171-expanded cord blood CD34+
Done for residual UM171 only (Ames, CHO micronucleus negative) plus cytogenetics of treated cells; none for cells

Summary across all 27 cell therapies →